The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This is heading to 3p in days on no news. The momentum could build and move the price a few pennies higher. With news there could be some serious price change that some on here would describe as “multibagging”. Patience.
Up she goes. A number of small significant buys and now a larger one have moved her up. The potential here is staggering. Medical solutions and progress, global deals, disruptive tech, and the serious prospect of a takeover.
Absolutely. Sell nowt. Buy low on low spread. Average down and build holding. Sit back and wait. Prof. Dawn and her partner went to same school as me so I trust them more than most and AS is a good steady serious player. Then there is the science and the opportunity for the human race. Hold hold hold.
Sorry postman but I agree with THG, we sold the interest in exchange for CDT shares which we now sell at considerable profit. That is the gain. Hopefully the drug is commercialised for the benefit of the world but the only impact for Vela will be moral.
A happy new year to all holders and patient investors. A nice quiet few days for bargain hunting. Agree re a notional quarterly report math issue, but given our belief in never saying anything sooner than ‘politely late’ we need not worry. Predict news on holdings, followed by some gentle CDT selling, then a delayed quarterly update, and who knows maybe some nice positive news from one or two of the core investments.
Buying the dips is going to become a new year pastime for a number of us I think. The piece of insight I’m after is what particular action followed by RNS will lead to a true share value share price alignment. The merger/sPAC didn’t quite do it, neither did the quarterly or six monthly nor the put option exercise. Next possibility is the first sale of a bunch of CDTs shares, otherwise I’m going to spending far too much time keeping an eye on the CDT sp.